)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Pharma Mar (PHM) investor relations material
Pharma Mar Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary31 Jul, 2025
Executive summary
Total revenues increased by 18% year-over-year to €95.3 million, with growth across all revenue streams, including recurring and nonrecurring income.
EBITDA reached €25.1 million, improving from negative €0.8 million, driven by strong licensing income and subsidies.
Net profit rose to €19.4 million, over five times higher than the prior year period.
Major regulatory milestones achieved for Zepzelca, including FDA priority review and EMA submission for SCLC.
R&D expenditure decreased to €47.5 million, with ongoing investment in oncology and RNAi clinical programs.
Financial highlights
Recurring revenue rose 5% to €72.2 million, with net sales up 9% to €45.8 million year-over-year.
Nonrecurring license revenues surged 87% to €23.0 million, mainly from a new Japanese license agreement.
Upfront payment of €22 million from a Japanese license agreement, with €21.7 million recognized as revenue by June 30.
Operating profit reached €21.1 million, compared to a loss of €3.9 million in 1H24.
Cash and equivalents plus financial investments totaled €182.9 million at period end.
Outlook and guidance
EMA review for first-line maintenance treatment in SCLC underway, with opinion expected by Q1 2026 and product launch preparations ongoing.
FDA PDUFA date for a key product set for October 7, with additional regulatory reviews in Israel, Switzerland, Australia, and Singapore expected soon after.
R&D spending expected to intensify in coming quarters due to new early-stage clinical developments.
SCLC trial results (LAGOON) anticipated in 1H26, with potential for expanded indications.
Anticipated inclusion of new combination therapy in NCCN guidelines following positive trial results.
Explain the decrease in royalties from Zepzelca.
Assess the impact of Sylentis' IPCEI grant.
When are the LAGOON trial results expected?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Pharma Mar earnings date
Q3 202531 Oct, 2025
Next Pharma Mar earnings date
Q3 202531 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Pharma Mar S.A. is a biopharmaceutical company specializing in the development of marine-derived drugs for oncology. It also operates diagnostics and RNA-based product divisions for healthcare applications. The company is headquartered in Colmenar Viejo, Spain, and its shares are listed on the BME.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage